Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Ixazomib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms Millennium
- 25 Mar 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.
- 25 Mar 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 30 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.